SPIMACO Pharmaceutical Company announced today on tadawul signing 5 years renewable agreement with Glaxo SmithKline Company (GSK) to market and distribute Respira product (Asthma treatment) in the Kingdom.
Respira is expected to be offered in the local markets during the first half of 2014 and expected to generate SAR 150m sales revenues per annum to SPIMACO.
.
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}